SPRED2 and Alzheimer disease: The levels of 17 NAbs (ADAM10, ADAMTS1, CLU, FERMT2, NDUFAF6, OARD1, PTK2B, SLC24A4, SORL1, SPPL2A, TREM2, WWOX, ADAMTS4, SPRED2, TMEM163, TSPAN14 and VKORC1), named the “Total 17 NAbs” panel, were still significantly lower in the AD group than in the CN group after Bonferroni correction (P < 0.002) (Fig. 1).